

IMPORTANT INFORMATION SHORTAGE NOTIFICATION



Ozempic® (semaglutide) solution for injection in pre-filled pen (EU/1/17/1251/002, 003, 005): supply shortage

21 December 2022

Dear Healthcare Professional,

Novo Nordisk Limited, Ireland would like to inform you of a temporary supply shortage with Ozempic® 0.25 mg and Ozempic® 0.5 mg solution for injection in pre-filled pen.

- Ozempic® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes¹.
- The shortage is expected to commence on 10-Jan-2023 with a return of stock expected in early February 2023. Updated information on the availability of Ozempic® 0.25 mg and Ozempic® 0.5 mg will be available on the shortages section of the Health Products Regulatory Authority (HPRA) website (www.hpra.ie).
- We kindly request your support to ensure that patients using Ozempic® are made aware of this supply shortage and that patients at risk of running out of Ozempic® are safely switched to another glucagon-like peptide-1 (GLP-1) receptor agonist or other suitable alternatives based on your clinical judgement.
- Delayed awareness of the out-of-stock situation may result in patients missing the required doses, which may have clinical consequences such as hyperglycaemia.

Ozempic® supply status

Increased demand for Ozempic® 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen has led to intermittent shortages globally which are expected to continue into 2023. The HPRA and the Corporate Pharmaceutical Unit of the HSE have been informed. The supply shortage is not related to a quality defect of the product or a safety issue.

To ensure long-term continuity of stable supply of Ozempic® to the Irish market, Novo Nordisk are releasing a proportional level of Ozempic® stock to secondary wholesalers on a month-by-month basis. Secondary wholesalers have also implemented proportional allocations at pharmacy level to ensure continuity of supply. As a result of the above actions, supply may not meet demand at pharmacy level and will result in intermittent delays in receiving stock of Ozempic® by pharmacies.

Novo Nordisk Limited, Ireland will continue to provide updates on this supply situation to the HPRA and HSE as new information becomes available. At Novo Nordisk we are working around the clock to maximise existing production while investing heavily in new capacity to remedy these shortages. We sincerely apologise for this unfortunate situation and any inconvenience it may cause.

Call for reporting

Adverse events including medication errors relating to Ozempic® FlexTouch® or alternative Novo Nordisk products should be reported to Novo Nordisk Medical Department at complaintireland@novonordisk.com or Tel: 01 8629700 or to the Health Products Regulatory Authority at www.hpra.ie.

Company contact point

Further information can be obtained by contacting Novo Nordisk Limited, Ireland on 01 8629700 or infoireland@novonordisk.com.

Yours sincerely

Dr Donna Sexton
Clinical, Medical and Regulatory Director
Novo Nordisk Limited, Ireland

References available overleaf

Reference: 1. Novo Nordisk. Ozempic® (semaglutide) Summary of Product Characteristics (SmPC). Revision date 09/2022. www.medicines.ie

Ozempic®, FlexTouch® and the Apis bull logo are registered trademarks owned by Novo Nordisk A/S.

Date of preparation: December 2022, IE22OZM00151

Novo Nordisk Limited,
First Floor, Block A
The Crescent Building
Northwood Business Park
Santry, Dublin 9
D09 X8W3, Ireland
www.novonordisk.ie
Tel: (01) 862 9700
infoireland@novonordisk.com